NOTICE OF ALLOWANCE - ISSUED
issued
on 30 Jul 2024
Last Applicant/ Owned by
10578 Science Drive, Suite 125
San Diego
CA
92121
Serial Number
98084156 filed on 13th Jul 2023
Registration Number
N/A
Correspondent Address
Aaron D. Hendelman
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
EXPLORE44-OLE
Medical and scientific research, namely, conducting clinical trials for others for oligonucleotide-based therapeutics in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the treatment of viral diseases and disorders, endocrine diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and di Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Medical and scientific research, namely, conducting clinical trials for others for oligonucleotide-based therapeutics in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the treatment of viral diseases and disorders, endocrine diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, neuromuscular diseases and disorders, rare muscle diseases, cardiomyopathies diseases and disorders, heart muscle diseases, muscular dystrophies, muscle atrophy diseases and disorders, genitourinary diseases and disorders, sexual dysfunction, oncological diseases and disorders, hepatological diseases and disorders, ophthalmic diseases and disorders, respiratory diseases and disorders, neurological diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, dermatological diseases and disorders and psychiatric diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; none of the aforementioned offerings being in the nature of dietetic substances for medical use, foods for special medical purposes, or special nutritional food products for medical purposes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Antibodies for medical purposes comprising oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral diseases and disorders, endocrine diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, neuromuscular diseases and disorders, rare muscle diseases, cardiomyopathies diseases and disorders, heart muscle diseases, muscular dystrophies, muscle atrophy diseases and disorders, genitourinary diseases and disorders, sexual dysfunction, oncological diseases and disorders, hepatological diseases and disorders, ophthalmic diseases and disorders, respiratory diseases and disorders, neurological diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, dermatological diseases and disorders and psychiatric diseases and disorders, none of the aforementioned offerings being in the nature of dietetic substances for medical use, foods for special medical purposes, or special nutritional food products for medical purposes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 98084156
Mark Type
No Service Mark
Attorney Docket Number
No 45532-TM1014
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 30th Jul 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 04th Jun 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 04th Jun 2024 | PUBLISHED FOR OPPOSITION |
| 15th May 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 01st May 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 25th Apr 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 25th Apr 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 25th Apr 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 26th Mar 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 26th Mar 2024 | NON-FINAL ACTION E-MAILED |